- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MERUS LABS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MPH HEALTH CARE | 27,100 | -0,73 % | MPH Health Care: In den schwarzen Zahlen | Im ersten Halbjahr kommt die Investmentgesellschaft MPH Health Care auf einen Gewinn von 5,0 Millionen Euro. Im Vorjahr gab es einen Verlust von 72,7 Millionen Euro. Das Ergebnis beruht auf den bilanztechnischen... ► Artikel lesen | |
| EYEPOINT | 3,040 | +1,33 % | EyePoint, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | ||
| AMARIN | 12,000 | +0,84 % | Amarin Corporation plc: Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence | Q2 2026 Results Highlight Global Volume Growth, Lower Operating Expenses and Positive Cash Flow For Full Year 2026, Company Expects Continued Growth in International Markets, Maintenance of VASCEPA's... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,150 | -0,49 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 458,00 | -0,72 % | Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| ANI PHARMACEUTICALS | 61,50 | +2,50 % | ANI Pharmaceuticals auf Wells Fargo Konferenz: Neuausrichtung auf seltene Erkrankungen wird beschleunigt | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| DOGECOIN CASH | - | - | Dogecoin Cash, Inc.: Dogecoin Cash Files Utility Patent For Blockchain Infrastructure Designed To Support Dogecoin Application Usability | Mesquite, NV, June 15, 2026 (GLOBE NEWSWIRE) -- Mesquite, NV - June 15, 2026 - Dogecoin Cash, Inc. (OTC: DOGP) today announced the filing of a U.S. utility patent application with the United States... ► Artikel lesen | |
| BLUM HOLDINGS | - | - | BLUM HOLDINGS, INC. - 15-12G, Securities registration termination | ||
| THERIVA BIOLOGICS | 0,228 | 0,00 % | Theriva Biologics, Inc.: Theriva Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results | - First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic... ► Artikel lesen | |
| BMP PHARMA TRADING | 7,400 | 0,00 % | PTA-News: B.M.P. Pharma Trading AG: deutliche Steigerung der Rentabilität im 1. Halbjahr 2026 - Rentabilitätsanstieg EBIT um 52,9% | DJ PTA-News: B.M.P. Pharma Trading AG: deutliche Steigerung der Rentabilität im 1. Halbjahr 2026 - Rentabilitätsanstieg EBIT um 52,9%
Unternehmensmitteilung für den Kapitalmarkt
B.M.P. Pharma... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 10,210 | +0,10 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer | Multicenter study to evaluate paxalisib plus gemcitabine for children and young adults with recurrent or progressive AT/RT, where no approved therapies currently... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,052 | +11,83 % | Allergy Therapeutics - Trading update for the year ended 30 June 2026 | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB |
MERUS LABS INTERNATIONAL INC gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MERUS LABS INTERNATIONAL INC finden Sie auf Wallstreet Online.